您现在的位置是:UK first to approve Casgevy gene therapy for blood disorders >>正文
UK first to approve Casgevy gene therapy for blood disorders
上海品茶网 - 夜上海最新论坛社区 - 上海千花论坛52人已围观
简介By subscribing, you agree to our Terms of Use and Policies You may unsubscribe at any time.Recently,...
By subscribing, you agree to our Terms of Use and Policies You may unsubscribe at any time.
Recently, scientists aiming to devise a one-time treatment to relieve symptoms and possibly cure genetic diseases have successfully found a solution.
A new study reported the development of Casgevy, a gene-editing tool made using CRISPR-Cas9 to treat two severe blood conditions – sickle-cell disease and β-thalassaemia. The process involves editing genes that encode hemoglobin in blood-producing stem cells.
UK medicines regulator – Medicines and Healthcare Products Regulatory Agency (MHRA) is the first to approve this therapy, following the success of clinical trials.
Prospects to employ future CRISPR therapies
Kay Davies, a geneticist at the University of Oxford, stated: “This is a landmark approval which opens the door for further applications of CRISPR therapies in the future for the potential cure of many genetic diseases.”
See Also Related- CRISPR-like system capable of editing human genome uncovered in eukaryotes
- Everything You Ever Wanted to Know About CRISPR
- CRISPR-based gene editing gets smaller, better "scissors"
- CRISPR Breakthrough: Scientists Can Now Turn Genes On and Off at Whim
According to Nature, the treatment is administered by intravenous infusion. Vertex Pharmaceuticals in Boston, Massachusetts, and CRISPR Therapeutics in Zug, Switzerland, developed the therapy.
Scientists alluding to the success of Casgevy exemplified that the therapy relieved patients of debilitating pain in sickle-cell disease and reduced or eliminated the need for regular blood transfusions in β-thalassaemia.
“The trial for sickle-cell disease has followed 29 out of 45 participants long enough to draw interim results. Casgevy completely relieved 28 of those people of debilitating episodes of pain for at least one year after treatment,” reported Nature.
In the trials for severe β-thalassemia, for which the standard treatment entails monthly blood transfusions. Nature reported that out of 54 individuals receiving Casgevy, 42 participated long enough to yield interim results. Among these, 39 didn't require a blood transfusion for a year, while the remaining three saw a reduction of over 70 percent in transfusion needs.
Revolutionary use of CRISPR-Cas9 tool
The revolutionary aspect of this therapy is its utilization of CRISPR-Cas9, a tool that won the Nobel Prize in Chemistry in 2020, to precisely edit genes in blood-producing stem cells.
By targeting a particular gene – BCL11A, Casgevy triggers the production of fetal hemoglobin, which can alleviate symptoms by improving oxygen supply to tissues.
However, clinical trials observed certain side effects in participants, including nausea and fever, but major safety concerns were undetected.
However, scientists noted concerns about potential unintended genetic modifications by CRISPR-Cas9, which are being monitored.
David Rueda, a geneticist at Imperial College London, told the SMC stated:
“It is well known that CRISPR can result in spurious genetic modifications with unknown consequences to the treated cells. It would be essential to see the whole-genome sequencing data for these cells before concluding. Nonetheless, this announcement makes me feel cautiously optimistic.”
Other countries, including the US and Europe, are reviewing Casgevy for approval. However, the high cost and complex technology involved might limit its accessibility, especially in low- and middle-income countries.
Calculations indicate that the therapy might cost around US$2 million per patient, posing a substantial accessibility limitation.
“The challenge is that these therapies will be very expensive, so a way of making these more accessible globally is key,” Davies noted.
A Vertex representative told Nature: “We have not established a list price for the UK at this time and are focused on working with the health authorities to secure reimbursement and access for eligible patients as quickly as possible.”
Tags:
转载:欢迎各位朋友分享到网络,但转载请说明文章出处“上海品茶网 - 夜上海最新论坛社区 - 上海千花论坛”。http://www.jz08.com.cn/news/16236.html
相关文章
ENO Token Lists on LATOKEN to Transform the Wine Industry
UK first to approve Casgevy gene therapy for blood disordersMexico City, Mexico, June 21st, 2023, ChainwireENO, the native token of an emerging wine industry pl...
阅读更多
Japanese C
UK first to approve Casgevy gene therapy for blood disordersBy subscribing, you agree to our Terms of Use and Policies You may unsubscribe at any time.TheJapan...
阅读更多
Bitcoin hard forks, Bitcoin Cash and Bitcoin SV in the spotlight with double
UK first to approve Casgevy gene therapy for blood disordersAt press time, BCH price had risen by 52% in the last seven days and 28% in the last 24 hours.BSV, o...
阅读更多
热门文章
- Brazil Sets Release Of Digital Real By 2022
- Zoomex X WSOT 2023: Unleash Your Trading Prowess and Race to $7 Million in Prizes!
- Monero price jumps 14% as bullseye yearly highs around $120
- Coinbase and PayPal join hands to offer crypto transactions in Europe
- Binance Report Outlines Outlook For Crypto Brokers
- Nobel laureate enters fray to generate energy using nuclear fusion
最新文章
Revolut to terminate US crypto services due to regulatory challenges
Bitcoin stays below $30k: Will inflation data push it higher?
“The People’s Coin” Spacemesh Launches Following Five Years of Research
Logan Paul under fire over $1 million bet proposal
New 'AI
Bitcoin dominance surging amid changing market dynamics and regulatory crackdown